Clinical Trials
7 trialsNCT07249905 2026-05-04
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT00002663 2023-02-13
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara Biotherapeutics
Phase 1/2 Completed
NCT00546793 2021-08-16
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Gilead Sciences
Phase 1/2 Completed
NCT01474681 2020-12-30
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
Phase 1/2 Completed
NCT00051597 2011-10-12
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Seagen Inc.
Phase 1/2 Completed